Low blood sugar (hypoglycaemia) is an important safety consideration for anyone taking retatrutide, an investigational triple receptor agonist currently being evaluated in clinical trials. Although retatrutide's glucose-dependent mechanism of action is designed to reduce hypoglycaemia risk compared with agents such as sulphonylureas or insulin, the risk is not eliminated — particularly when retatrutide is used alongside other glucose-lowering therapies. This article explains how retatrutide affects blood glucose, who is most at risk, how to recognise and manage hypoglycaemia, and practical steps to monitor your blood sugar safely.

How Retatrutide Affects Blood Sugar Levels

Retatrutide stimulates insulin release in a glucose-dependent manner via GLP-1 and GIP receptors, theoretically reducing hypoglycaemia risk, though its full safety profile — including the effect of glucagon receptor agonism — is still being established in ongoing trials.

Retatrutide is an investigational triple receptor agonist that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. This triple mechanism distinguishes it from existing agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 agonist). GLP-1 and GIP receptor activation promotes insulin secretion in a glucose-dependent manner and contributes to appetite suppression; slowing of gastric emptying is primarily a GLP-1–mediated effect. The role of glucagon receptor activation is more complex: glucagon normally raises blood glucose, and how its modulation interacts with insulin dynamics in a triagonist context is still being studied.

The glucose-dependent nature of GLP-1 and GIP receptor stimulation is an important safety feature, as these receptors stimulate insulin release primarily when blood glucose is already elevated. This theoretically reduces the risk of hypoglycaemia compared with agents such as sulphonylureas or insulin. However, the net effect of simultaneous glucagon receptor agonism on hypoglycaemia risk has not yet been fully established, and the overall safety profile continues to be evaluated in ongoing trials.

As of 2024, retatrutide has not received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). There is no UK Summary of Product Characteristics (SmPC) or EMA EPAR, and use is currently limited to clinical trials. Phase 2 trial data (published in the New England Journal of Medicine, 2023) have demonstrated significant weight loss and improvements in glycaemic markers, but the complete safety profile — including the precise risk of low blood sugar — continues to be characterised. Patients should be aware that information may evolve as further trial data become available.

If you believe you are experiencing a side effect related to any medicine, you can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Recognising the Symptoms of Low Blood Sugar (Hypoglycaemia)

Hypoglycaemia is defined as blood glucose below 4 mmol/L; early warning signs include shakiness, sweating, palpitations, and dizziness, while severe episodes can cause seizures or loss of consciousness.

Hypoglycaemia is generally defined as a blood glucose level below 4 mmol/L, though symptoms can vary between individuals. Recognising the early warning signs is essential for prompt self-management and to prevent progression to more serious episodes.

Early symptoms of hypoglycaemia may include:

• Shakiness or trembling

• Sweating, particularly cold or clammy skin

• Palpitations or a rapid heartbeat

• Hunger or nausea

• Dizziness or light-headedness

• Difficulty concentrating or feeling confused

• Irritability or anxiety

• Pallor (looking pale)

If blood glucose continues to fall without intervention, symptoms can become more severe. Later or more serious signs include:

• Slurred speech

• Blurred or double vision

• Severe confusion or disorientation

• Seizures

• Loss of consciousness

It is worth noting that some individuals — particularly those who have experienced frequent hypoglycaemic episodes or who have had diabetes for many years — may develop hypoglycaemia unawareness, where the usual warning signs are absent or blunted. This significantly increases the risk of a severe episode. Anyone who suspects they may have hypoglycaemia unawareness should discuss this with their GP or diabetes care team promptly.

Whilst retatrutide's glucose-dependent mechanism reduces the theoretical risk of hypoglycaemia when used alone, the risk can increase — particularly when it is combined with insulin or sulphonylureas — and dose reduction of those medicines may be needed. Further information on symptoms and thresholds is available from the NHS (nhs.uk) and Diabetes UK (diabetes.org.uk).

Who Is Most at Risk of Hypoglycaemia on Retatrutide

Patients concurrently taking sulphonylureas or insulin, those with renal impairment, older adults, and individuals significantly reducing caloric intake due to appetite suppression are at greatest risk of hypoglycaemia on retatrutide.

Although retatrutide's mechanism of action is designed to minimise the risk of hypoglycaemia when used as monotherapy, certain groups of patients may face a higher risk, particularly as the drug is being studied in populations already managing type 2 diabetes or obesity with existing medications.

Individuals at greater risk of low blood sugar whilst taking retatrutide include:

• Those concurrently prescribed sulphonylureas (e.g., gliclazide, glibenclamide), which stimulate insulin release independently of blood glucose levels — dose reduction is often required when initiating potent incretin-based therapies

• Patients using insulin therapy, where doses may need to be reduced as glycaemic control improves or caloric intake falls

• People with renal impairment, who may have a generally increased risk of hypoglycaemia, particularly if also taking insulin or sulphonylureas (note: the specific effect of renal impairment on retatrutide clearance has not yet been established, as no SmPC exists)

• Individuals who are fasting, following a very low-calorie diet, or who have significantly reduced their food intake — a common occurrence given retatrutide's appetite-suppressing effects

• Those with a history of hypoglycaemia or hypoglycaemia unawareness

• Older adults, who may have reduced counter-regulatory responses to falling blood glucose

The appetite suppression associated with retatrutide can lead to substantially reduced caloric intake, which — whilst beneficial for weight loss — may necessitate a review and reduction of concomitant glucose-lowering therapies. NICE guidance on type 2 diabetes management (NG28) supports an individualised approach to minimising hypoglycaemia risk, including reviewing medication regimens when clinically significant changes in diet, weight, or glycaemic control occur. Patients and clinicians should work collaboratively to reassess treatment plans, particularly in the early weeks of retatrutide use when appetite changes and weight loss are most pronounced.

What to Do If Your Blood Sugar Drops Too Low

Take 15–20 g of fast-acting carbohydrate immediately, recheck blood glucose after 10–15 minutes, and repeat if levels remain below 4 mmol/L; call 999 if the person is unconscious or unable to swallow.

If you suspect your blood glucose has dropped too low, it is important to act quickly. The following steps are consistent with NHS and Diabetes UK guidance for conscious adults.

• Immediate steps for a conscious adult experiencing hypoglycaemia:
• Take 15–20 g of fast-acting carbohydrate, such as:
• 4–5 glucose tablets
• 150–200 ml of a sugary (non-diet) fizzy drink
• A small glass of fruit juice
• 5–6 jelly babies
• Wait 10–15 minutes, then recheck your blood glucose if you have a monitor available.
• If blood glucose remains below 4 mmol/L, repeat the fast-acting carbohydrate.
• Once blood glucose has recovered, eat your next meal or a small starchy snack (e.g., a plain biscuit or slice of bread) if a meal is not due soon, to help stabilise levels.

Do not use high-fat foods such as chocolate as a first-line treatment, as fat slows glucose absorption.

If a person becomes unconscious or is unable to swallow safely, do not attempt to give food or drink by mouth. Call 999 immediately. If a glucagon emergency kit is available — either an injection or a nasal powder (Baqsimi) — and someone present is trained to use it, this should be administered whilst awaiting emergency services.

Contact your GP or diabetes care team if you experience a severe hypoglycaemic episode, a nocturnal episode, recurrent episodes, or if your diet or medication has recently changed. These situations may indicate that your glucose-lowering therapy requires adjustment, particularly if retatrutide has led to significant changes in appetite or weight. For isolated, mild episodes that resolve promptly and have a clear cause, routine emergency contact is not always necessary, but do discuss any pattern of low readings at your next appointment.

Monitoring and Reducing Your Risk While Taking Retatrutide

Regular blood glucose monitoring — via finger-prick testing or continuous glucose monitoring where clinically indicated — combined with carrying fast-acting glucose and reviewing concomitant medications, is key to minimising hypoglycaemia risk on retatrutide.

Proactive monitoring and lifestyle awareness are key to minimising the risk of low blood sugar whilst taking retatrutide, particularly for those on combination glucose-lowering therapy.

Blood glucose monitoring is recommended for anyone at risk of hypoglycaemia. Depending on your individual circumstances, your GP or diabetes team may advise:

• Self-monitoring of blood glucose (SMBG) using a finger-prick glucometer, particularly before meals, after exercise, and before driving

• Continuous glucose monitoring (CGM) or flash glucose monitoring, which provide real-time or on-demand glucose readings and can alert users to falling levels. In line with NICE NG28, CGM is primarily recommended on the NHS for adults with type 2 diabetes who are on multiple daily insulin injections, or for those who meet other defined clinical criteria; your diabetes team can advise whether you are eligible

Practical steps to reduce your risk include:

• Informing your healthcare team of all medications you are taking, including over-the-counter products and supplements

• Not skipping meals, even if your appetite is significantly reduced — small, regular meals can help maintain stable glucose levels

• Carrying fast-acting glucose with you at all times

• Wearing a medical alert bracelet or carrying identification indicating your diabetes status and medications

• Avoiding excessive alcohol, which can impair the liver's ability to release glucose and mask hypoglycaemia symptoms

• Discussing any planned changes to diet or exercise with your care team before making them

Driving safety is an important consideration if you are at risk of hypoglycaemia. The DVLA publishes specific guidance for drivers with diabetes who take glucose-lowering medications (available at gov.uk/diabetes-driving). Depending on your treatment, you may have a legal obligation to notify the DVLA of your condition, and there are defined rules around blood glucose levels before and during driving. Group 2 licence holders (lorry and bus drivers) face additional requirements. If you have any concerns, speak to your GP, diabetes specialist nurse, or pharmacist for personalised advice.

If you experience any suspected side effects whilst taking retatrutide as part of a clinical trial, report these via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions